New biomarkers in T-cell lymphomas

被引：21

作者：

Bisig, Bettina ^{[2
,3
]}

Gaulard, Philippe ^{[4
,5
,6
]}

de Leval, Laurence ^{[1
,3
]}

机构：

[1] CHU Vaudois, Inst Pathol, Lausanne, Switzerland

[2] Ctr Hosp Univ Sart Taman, Dept Pathol, Liege, Belgium

[3] Univ Liege, Lab Expt Pathol, Grp Interdisciplinaire Genoprote Appl GIGA Res, B-4000 Liege, Belgium

[4] Grp Hosp Henri Mondor Albert Chenevie, Assistance Publ Hop Paris AP HP, Dept Pathol, Creteil, France

[5] Inst Natl Sante & Rech Med INSERM, U955, F-94010 Creteil, France

[6] Univ Paris Est, Fac Med, Creteil, France

来源：

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY | 2012年 / 25卷 / 01期

关键词：

peripheral T-cell lymphomas; biomarkers translocations; gene expression profiling; targeted therapy; prognosis; NF-KAPPA-B; GENE-EXPRESSION ANALYSIS; FOLLICULAR HELPER-CELLS; FACTOR RECEPTOR-ALPHA; SYK TYROSINE KINASE; CD52; EXPRESSION; PROGNOSTIC-SIGNIFICANCE; SIGNALING MOLECULES; BRENTUXIMAB VEDOTIN; NK CELLS;

D O I：

10.1016/j.beha.2012.01.004

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Peripheral T-cell lymphomas (PTCLs) are heterogeneous and uncommon malignancies characterized by an aggressive clinical course and a mostly poor outcome with current treatment strategies. The recent genome-wide molecular characterization of several entities has provided novel insights into their pathobiology and led to the identification of new biomarkers with diagnostic, prognostic or therapeutic implications for PTCL patients. Cell lineage and differentiation antigens (markers of y delta or NK lineage, of cytotoxicity, of follicular helper T cells) reflect the tumour's biological behaviour, and their detection in tissue samples may refine the diagnostic and prognostic stratification of the patients. Previously unrecognized gene rearrangements are being discovered (ITK-SYK translocation, IRF4/MUM1 and DUSP22 rearrangements), and may serve as diagnostic genetic markers. Deregulated molecules within oncogenic pathways (NF-kappa B, Syk, PDGFR alpha) and immunoreactive cell-surface antigens (CD30, CD52) have been brought to the fore as potential targets for guiding the development of novel therapies. (C) 2012 Elsevier Ltd. All rights reserved.

引用

页码：13 / 28

页数：16

共 107 条

[1] The role of CD30 in the pathogenesis of haematopoietic malignancies [J].